基于机器学习的代偿期肝硬化静脉曲张筛查模型的开发与验证(CHESS2001):一项国际多中心研究
研究基于肝脏硬度、血小板计数和总胆红素构建机器学习模型ML EGD,用于代偿期肝硬化患者排除高危静脉曲张。在训练队列中ML EGD避免52.6%不必要胃镜、漏诊高危静脉曲张率3.6%,验证队列避免58.1%、漏诊率1.4%,两个外部测试队列分别避免52.4%和41.1%,漏诊率分别为2.8%和3.1%,各队列避免胃镜比例均高于Baveno VI标准(P < .001)。
要点
- ML EGD基于肝脏硬度、血小板计数和总胆红素三个变量构建,并提供免费网页计算器。
- 各队列中ML EGD避免胃镜的比例为41.1%–58.1%,漏诊高危静脉曲张率为1.4%–3.6%。
- 与Baveno VI标准相比,ML EGD在所有队列中避免更多筛查胃镜(P < .001)。
核心结论
- 研究识别出基于肝脏硬度、血小板计数和总胆红素的新模型ML EGD,作为免费网页计算器,可有效帮助代偿期肝硬化患者排除高危静脉曲张并避免不必要的胃镜。
研究设计与样本
- 国际多中心队列研究(CHESS2001),纳入中国、新加坡和印度17家机构的2794例患者。
- 来自中国1所大学医院的1283例真实世界队列用于开发和内部验证,按9:1随机分为训练队列(n = 1154)和验证队列(n = 129)。
- 外部测试包括来自中国14所大学医院的966例患者(测试队列1)和来自新加坡及印度2家医院的545例患者(测试队列2)。
- 通过Shapley加性解释选取重要性评分前3的变量(肝脏硬度、血小板计数和总胆红素),输入轻量梯度提升机算法构建ML EGD。
- 临床试验注册号:NCT04307264。
主要发现
- 训练队列中ML EGD避免607例(52.6%)不必要胃镜,漏诊高危静脉曲张率为3.6%。
- 验证队列中ML EGD避免75例(58.1%)胃镜,漏诊高危静脉曲张率为1.4%。
- 测试队列1中ML EGD避免506例(52.4%)胃镜,漏诊高危静脉曲张率为2.8%。
- 测试队列2中ML EGD避免224例(41.1%)胃镜,漏诊高危静脉曲张率为3.1%。
- 与Baveno VI标准相比,ML EGD在所有队列中避免更多筛查胃镜:训练队列52.6% vs 29.4%,验证队列58.1% vs 44.2%,测试队列1 52.4% vs 26.5%,测试队列2 41.1% vs 21.1%(P < .001)。
关键数值与推荐
- ML EGD模型输入变量为肝脏硬度、血小板计数和总胆红素。
- ML EGD网页计算器免费开放访问(http://www.pan-chess.cn/calculator/MLEGD_score)。
- 与Baveno VI标准比较,各队列避免胃镜比例差异的P < .001。
临床怎么用
- ML EGD可作为免费网页计算器用于代偿期肝硬化患者排除高危静脉曲张,帮助避免不必要的胃镜。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The prevalence of high-risk varices (HRV) is low among compensated cirrhotic patients undergoing EGD. Our study aimed to identify a novel machine learning (ML)-based model, named ML EGD, for ruling out HRV and avoiding unnecessary EGDs in patients with compensated cirrhosis. METHODS: An international cohort from 17 institutions from China, Singapore, and India were enrolled (CHESS2001). The variables with the top 3 importance scores (liver stiffness, platelet count, and total bilirubin) were selected by the Shapley additive explanation and input into a light gradient-boosting machine algorithm to develop ML EGD for identification of HRV. Furthermore, we built a web-based calculator for ML EGD, which is free with open access (http://www.pan-chess.cn/calculator/MLEGD_score). Unnecessary EGDs that were not performed and the rates of missed HRV were used to assess the efficacy and safety for varices screening. RESULTS: Of 2794 enrolled patients, 1283 patients formed a real-world cohort from 1 university hospital in China used to develop and internally validate the performance of ML EGD for varices screening. They were randomly assigned into the training (n = 1154) and validation (n = 129) cohorts with a ratio of 9:1. In the training cohort, ML EGD spared 607 (52.6%) unnecessary EGDs with a missed HRV rate of 3.6%. In the validation cohort, ML EGD spared 75 (58.1%) EGDs with a missed HRV rate of 1.4%. To externally test the performance of ML EGD, 966 patients from 14 university hospitals in China (test cohort 1) and 545 from 2 hospitals in Singapore and India (test cohort 2) comprised the 2 test cohorts. In test cohort 1, ML EGD spared 506 (52.4%) EGDs with a missed HRV rate of 2.8%. In test cohort 2, ML EGD spared 224 (41.1%) EGDs with a missed HRV rate of 3.1%. When compared with the Baveno VI criteria, ML EGD spared more screening EGDs in all cohorts (training cohort, 52.6% vs 29.4%; validation cohort, 58.1% vs 44.2%; test cohort 1, 52.4% vs 26.5%; test cohort 2, 41.1% vs 21.1%, respectively; P < .001). CONCLUSIONS: We identified a novel model based on liver stiffness, platelet count, and total bilirubin, named ML EGD, as a free web-based calculator. ML EGD could efficiently help rule out HRV and avoid unnecessary EGDs in patients with compensated cirrhosis. (Clinical trial registration number: NCT04307264.).
引用
- Huang Y, Li J, Zheng T, et al. Development and validation of a machine learning-based model for varices screening in compensated cirrhosis (CHESS2001): an international multicenter study. Gastrointest Endosc. 2022. PMID: 36252870. doi:10.1016/j.gie.2022.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。